PRA Health Sciences (PRAH) Tops Q4 EPS by 7c

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $0.71, $0.07 better than the analyst estimate of $0.64. Revenue for the quarter came in at $413.6 million versus the consensus estimate of $405.04 million.

GUIDANCE:

PRA Health Sciences sees FY2017 Adj. EPS of $3.08-$3.18, versus the consensus of $2.96.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance